Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia.
Preclinical studies have shown that phosphodiesterase inhibitors (PDE-Is) represent a potential pharmacological strategy for the treatment of brain ischemia sequelea. PDE-Is 3, 4 and 5 have been tested in several brain ischemia models. All the three PDE-Is after acute or chronic treatment decreased the degree of neurodegeneration and most of them improved functional recovery after brain injury by specific cellular and molecular mechanisms mainly involving an anti-inflammatory and/or neuroprotection action. In contrast to the large number of investigations using PDE-Is in experimental brain ischemia research, the number of clinical studies is still limited. The purpose of this review is to summarize the data currently available on the effects of PDE-Is in experimental models of cerebral ischemia.
Lígia Mendes
LM
Soares
Jos
J
Prickaerts
Humberto
H
Milani
Elaine
E
Del Bel
Harry Wilhelm Maria
HW
Steinbusch
Department of Pharmacology and Therapeutics, State University of Maringa, Av. Colombo, 5790, CEP 87020-900, Maringa, Parana, Brazil. rmmwoliveira@uem.br.
Rúbia Maria Weffort
RM
de Oliveira
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism
D018696:Neuroprotective Agents; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases